Payment overview · 2025
General Payments
$727.43
40 reported records · 11 companies
Healthcare provider profile · identity verified
Andrew C Bryson, M.D.
Allopathic & Osteopathic Physicians|Family Medicine · POCAHONTAS, AR · NPI 1861021040
Verified facts
What the public records show
CMS Open Payments records show Andrew C Bryson, M.D. received $727.43 in general payments during 2025 across 40 reported records.
AstraZeneca Pharmaceuticals LP accounted for 42.3% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 17 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Eliquis, Farxiga, Ozempic.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 68 claims for Farxiga by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LOKELMA as an associated drug or biological on 6897 records involving 4326 distinct recipient NPIs. Public Medicare Part D data also shows 15 claims for Lokelma by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYMBICORT as an associated drug or biological on 71 records involving 51 distinct recipient NPIs. Public Medicare Part D data also shows 12 claims for Symbicort by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 102 claims for Ozempic by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 60 claims for Eliquis by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $307.44 | 42.3% | 13 | 2025 |
| Otsuka America Pharmaceutical, Inc. | Unresolved — no canonical attribution shown | $84.51 | 11.6% | 4 | 2025 |
| Amgen Inc. | Unresolved — no canonical attribution shown | $84.04 | 11.6% | 6 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $71.22 | 9.8% | 4 | 2025 |
| Sumitomo Pharma America, Inc. | Unresolved — no canonical attribution shown | $57.39 | 7.9% | 3 | 2025 |
| Phathom Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $47.25 | 6.5% | 5 | 2025 |
| ABBVIE INC. | Unresolved — no canonical attribution shown | $16.64 | 2.3% | 1 | 2025 |
| Salix Pharmaceuticals, a division of Bausch Health US, LLC | Unresolved — no canonical attribution shown | $16.60 | 2.3% | 1 | 2025 |
| Exact Sciences Corporation | Unresolved — no canonical attribution shown | $14.34 | 2.0% | 1 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $14.01 | 1.9% | 1 | 2025 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | Unresolved — no canonical attribution shown | $13.99 | 1.9% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $727.43 | 40 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| AIRSUPRA Normalized: airsupra |
Drug | AstraZeneca Pharmaceuticals LP | $249.18 | 9 | 2025 |
Source payment records
|
|||||
| BREZTRI Normalized: breztri |
Drug | AstraZeneca Pharmaceuticals LP | $185.99 | 5 | 2025 |
Source payment records
|
|||||
| FARXIGA Normalized: farxiga |
Drug | AstraZeneca Pharmaceuticals LP | $127.73 | 1 | 2025 |
Source payment records
|
|||||
| REXULTI Normalized: rexulti |
Drug | Otsuka America Pharmaceutical, Inc. | $84.51 | 4 | 2025 |
Source payment records
|
|||||
| REPATHA Normalized: repatha |
Biological | Amgen Inc. | $84.04 | 6 | 2025 |
Source payment records
|
|||||
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $71.22 | 4 | 2025 |
Source payment records
|
|||||
| OTEZLA Normalized: otezla |
Drug | Amgen Inc. | $69.74 | 5 | 2025 |
Source payment records
|
|||||
| GEMTESA Normalized: gemtesa |
Drug | Sumitomo Pharma America, Inc. | $57.39 | 3 | 2025 |
Source payment records
|
|||||
| Rybelsus Normalized: rybelsus |
Drug | Novo Nordisk Inc | $52.75 | 3 | 2025 |
Source payment records
|
|||||
| VOQUEZNA Normalized: voquezna |
Drug | Phathom Pharmaceuticals, Inc. | $47.25 | 5 | 2025 |
Source payment records
|
|||||
| QULIPTA Normalized: qulipta |
Drug | ABBVIE INC. | $16.64 | 1 | 2025 |
Source payment records
|
|||||
| UBRELVY Normalized: ubrelvy |
Drug | ABBVIE INC. | $16.64 | 1 | 2025 |
Source payment records
|
|||||
| XIFAXAN Normalized: xifaxan |
Drug | Salix Pharmaceuticals, a division of Bausch Health US, LLC | $16.60 | 1 | 2025 |
Source payment records
|
|||||
| Cologuard Collection Kit Normalized: cologuard collection kit |
Device | Exact Sciences Corporation | $14.34 | 1 | 2025 |
Source payment records
|
|||||
| ELIQUIS Normalized: eliquis |
Drug | PFIZER INC. | $14.01 | 1 | 2025 |
Source payment records
|
|||||
| NURTEC ODT Normalized: nurtec odt |
Drug | PFIZER INC. | $14.01 | 1 | 2025 |
Source payment records
|
|||||
| CAPLYTA Normalized: caplyta |
Drug | ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | $13.99 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| ELIQUIS eliquis |
2025 | Eliquis | 2024 | 60 | exact normalized | Medicare Part D |
| FARXIGA farxiga |
2025 | Farxiga | 2024 | 68 | exact normalized | Medicare Part D |
| Ozempic ozempic |
2025 | Ozempic | 2024 | 102 | exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
68 | 13 |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | LOKELMA open payments reported associated product |
CMS Open Payments — General Payments 6897 supporting records · 4326 recipient NPIs · example record 1206131624 |
Lokelma · 2024 Exact normalized brand match · 1 Part D row |
15 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | SYMBICORT open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 51 recipient NPIs · example record 1206132610 |
Symbicort · 2024 Exact normalized brand match · 1 Part D row |
12 | suppressed by CMS |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
102 | 21 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
60 | 11 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 193 | 65 |
| Gabapentin | Gabapentin | 131 | 35 |
| Lisinopril | Lisinopril | 130 | 46 |
| Omeprazole | Omeprazole | 119 | 35 |
| Duloxetine Hcl | Duloxetine Hcl | 114 | 25 |
| Amlodipine Besylate | Amlodipine Besylate | 110 | 42 |
| Levothyroxine Sodium | Levothyroxine Sodium | 110 | 38 |
| Ozempic | Semaglutide | 102 | 21 |
| Potassium Chloride | Potassium Chloride | 88 | 29 |
| Furosemide | Furosemide | 83 | 28 |
| Farxiga | Dapagliflozin Propanediol | 68 | 13 |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 67 | 15 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 64 | 24 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 61 | 26 |
| Eliquis | Apixaban | 60 | 11 |
| Pantoprazole Sodium | Pantoprazole Sodium | 59 | 21 |
| Escitalopram Oxalate | Escitalopram Oxalate | 56 | 17 |
| Chlorthalidone | Chlorthalidone | 53 | 15 |
| Jardiance | Empagliflozin | 53 | 17 |
| Mirtazapine | Mirtazapine | 51 | 17 |
| Tramadol Hcl | Tramadol Hcl | 51 | 19 |
| Losartan Potassium | Losartan Potassium | 49 | 19 |
| Meloxicam | Meloxicam | 49 | 26 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 48 | 24 |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 48 | 14 |
| Metformin Hcl | Metformin Hcl | 43 | 18 |
| Hydrochlorothiazide | Hydrochlorothiazide | 42 | 18 |
| Trazodone Hcl | Trazodone Hcl | 42 | 20 |
| Celecoxib | Celecoxib | 40 | suppressed |
| Tamsulosin Hcl | Tamsulosin Hcl | 39 | 16 |
| Buspirone Hcl | Buspirone Hcl | 38 | 13 |
| Ropinirole Hcl | Ropinirole Hcl | 38 | suppressed |
| Tresiba Flextouch U-100 | Insulin Degludec | 38 | suppressed |
| Allopurinol | Allopurinol | 37 | suppressed |
| Famotidine | Famotidine | 35 | 14 |
| Metoprolol Succinate | Metoprolol Succinate | 32 | 12 |
| Fluticasone Propionate | Fluticasone Propionate | 31 | 17 |
| Carvedilol | Carvedilol | 30 | 17 |
| Fluoxetine Hcl | Fluoxetine Hcl | 30 | 11 |
| Mounjaro | Tirzepatide | 30 | suppressed |
| Ezetimibe | Ezetimibe | 28 | 12 |
| Pregabalin | Pregabalin | 28 | suppressed |
| Entresto | Sacubitril/Valsartan | 27 | suppressed |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 27 | suppressed |
| Primidone | Primidone | 27 | suppressed |
| Donepezil Hcl | Donepezil Hcl | 26 | suppressed |
| Metoprolol Tartrate | Metoprolol Tartrate | 26 | 12 |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 25 | 22 |
| Bupropion Xl | Bupropion Hcl | 25 | suppressed |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 25 | 14 |
| Tizanidine Hcl | Tizanidine Hcl | 24 | 11 |
| Metformin Hcl Er | Metformin Hcl | 23 | suppressed |
| Montelukast Sodium | Montelukast Sodium | 23 | suppressed |
| Lamotrigine | Lamotrigine | 22 | suppressed |
| Memantine Hcl | Memantine Hcl | 22 | suppressed |
| Pravastatin Sodium | Pravastatin Sodium | 22 | suppressed |
| Baclofen | Baclofen | 21 | suppressed |
| Clopidogrel | Clopidogrel Bisulfate | 21 | suppressed |
| Mupirocin | Mupirocin | 21 | suppressed |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 21 | suppressed |
| Prednisone | Prednisone | 20 | 20 |
| Zolpidem Tartrate | Zolpidem Tartrate | 20 | suppressed |
| Dapagliflozin | Dapagliflozin Propanediol | 18 | suppressed |
| Diltiazem 24hr Er (La) | Diltiazem Hcl | 18 | suppressed |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 18 | 16 |
| Alprazolam | Alprazolam | 17 | suppressed |
| Cephalexin | Cephalexin | 17 | 14 |
| Ventolin Hfa | Albuterol Sulfate | 17 | suppressed |
| Brimonidine Tartrate | Brimonidine Tartrate | 16 | suppressed |
| Estradiol | Estradiol | 16 | suppressed |
| Propranolol Hcl | Propranolol Hcl | 16 | suppressed |
| Sertraline Hcl | Sertraline Hcl | 16 | suppressed |
| Valsartan | Valsartan | 16 | suppressed |
| Lokelma | Sodium Zirconium Cyclosilicate | 15 | suppressed |
| Topiramate | Topiramate | 15 | suppressed |
| Alendronate Sodium | Alendronate Sodium | 14 | suppressed |
| Amlodipine-Olmesartan | Amlodipine Bes/Olmesartan Med | 14 | suppressed |
| Risperidone | Risperidone | 14 | suppressed |
| Simvastatin | Simvastatin | 14 | suppressed |
| Breztri Aerosphere | Budesonide/Glycopyr/Formoterol | 13 | suppressed |
| Myrbetriq | Mirabegron | 13 | suppressed |
| Sotalol | Sotalol Hcl | 13 | suppressed |
| Spiriva Respimat | Tiotropium Bromide | 13 | suppressed |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 13 | suppressed |
| Anoro Ellipta | Umeclidinium Brm/Vilanterol Tr | 12 | suppressed |
| Levalbuterol Hcl | Levalbuterol Hcl | 12 | suppressed |
| Oxycodone Hcl | Oxycodone Hcl | 12 | suppressed |
| Symbicort | Budesonide/Formoterol Fumarate | 12 | suppressed |
| Propranolol Hcl Er | Propranolol Hcl | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $727.43 · 40 records | AstraZeneca Pharmaceuticals LP | AIRSUPRA, BREZTRI, CAPLYTA, Cologuard Collection Kit, ELIQUIS, FARXIGA, GEMTESA, NURTEC ODT, OTEZLA, Ozempic, QULIPTA, REPATHA, REXULTI, Rybelsus, UBRELVY, VOQUEZNA, XIFAXAN | 5 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Eliquis play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with AstraZeneca Pharmaceuticals LP?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error